The effect of anticoagulants on cancer risk and survival: Systematic review

Cancer Treatment Reviews

Volumn 33, Issue 4, 2007, Pages 358-368

  Tagalakis, Vicky ^a   Blostein, Mark ^a   Robinson Cohen, Cassianne ^a   Kahn, Susan R ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cancer; Low molecular weight heparin; Mortality; Prevention; Therapy; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CERTOPARIN; COUMARIN; DALTEPARIN; DICOUMAROL; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PLACEBO; TINZAPARIN; WARFARIN;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST SURGERY; CANCER INHIBITION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG MECHANISM; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MEDLINE; MELANOMA; META ANALYSIS; METASTASIS INHIBITION; MONOTHERAPY; OVERALL SURVIVAL; PELVIS CANCER; PELVIS SURGERY; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; UROGENITAL TRACT CANCER; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; WARFARIN;

EID: 34248525326     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.02.004     Document Type: Review

References (73)

1. Smorenburg A.M., and Van Noorden C.J.F. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53 (2001) 93-97
2. Levitan N., Dowlatti A., Remcik S.C., Tahsildar H.I., Sivinski L.D., Beyth R., et al. Rates of initial and recurrent thromboemebolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine 78 (1999) 405-409
3. Sorensen H.T., Mellemkjaer L., Steffensen F.H., Olsen J.H., and Nielsen G.L. The risk of diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 338 (1998) 1169-1173
4. Hejna M., Raderer M., and Zielnski C.C. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91 (1999) 22-36
5. Falanga A., Marchetti M., Vignoli A., and Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumour progression. Clin Adv Hematol Oncol 1 (2003) 673-678
6. Holmer E., Mattsson C., and Nilsoon S. Anticoagulant and antithrombotic effects of heparin and low molecular weight heparin fragments in rabbits. Thromb Res 25 (1982) 475-485
7. Schulman S., Rhedin A.S., Lindmarker P., Carlsson A., Larfars G., Nicol P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 342 (2000) 1953-1958
8. Taliani M.R., Agnelli G., Prandoni P., Becattini C., Moia M., Bazzan M., et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 1 (2003) 1730-1733
9. Blumentals W.A., Foulis P.R., Schwartz S.W., and Mason T.J. Does warfarin therapy influence the risk of bladder cancer?. J Thromb Haemost 91 (2004) 801-805
10. Zacharski L.R., Henderson W.G., Rickles F.R., Forman W.B., Cornell Jr. C.J., Forcier R.J., et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA cooperative study #75. Cancer 53 10 (1984) 2046-2052
11. Daly L. The first international urokinase/warfarin trial in colorectal cancer. Clin Exp Meta 9 1 (1991) 3-11 Jan-Feb
12. Levine M., Hirsh J., Gent M., Arnold A., Warr D., Falanga A., et al. Double-blind randomized trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343 8902 (1994) 886-889
13. Stanford C.F. Anticoagulants in the treatment of small cell carcinoma of the bronchus. Thorax 34 (1979) 113-116
14. Zacharski L.R., Henderson W.G., Rickles F.R., Forman W.B., Cornell Jr. C.J., Forcier R.J., et al. Effect of warfarin on survival in small cell carcinoma of the lung: Veterans Administration Study No. 75. JAMA 245 8 (1981) 831-835
15. Chahinian A.P., Propert K.J., Ware J.H., Zimmer B., Perry M.C., Hirsh V., et al. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J Clin Oncol 7 8 (1989) 993-1002
16. Maurer L.H., Herndon II J.E., Hollis D.R., Aisner J., Carey R.W., Skarin A.T., et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a cancer and leukemia group B study. J Clin Oncol 15 11 (1997) 3378-3387
17. Thornes R.D., Daly L., Lynch G., Breslin B., Browne H., Browne H.Y., et al. Treatment with coumarin to prevent or delay recurrence of malignant melanoma. J Cancer Res Clin Oncol 120 Suppl (1994) S32-S34
18. Thornes R.D. Oral anticoagulant therapy of human cancer. J Med 5 (1974) 83-91
19. Zacharski L.R., Memoli V.A., Morain W.D., Schlaeppi J.M., and Rousseau S.M. Cellular localization of enzymatically active thrombin in intact human tissues by hirudin binding. Thromb Haemost 73 5 (1995) 793-797
20. Smorenburg S.M., Vink R., Otten H.M., Swaneveld F., Buller H.R., et al. The effects of Vitamin K-antagonists on survival of patients with malignancy: a systematic analysis. J Thromb Haemost 86 (2001) 1586-1587
21. Prandoni P., Lensing A.W., Buller H.R., Carta M., Cogo A., Vigo M., et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 339 8791 (1992) 441-445
22. von Tempelhoff G.F., Harenberg J., Niemann F., Hommel G., Kirkpatrick C.J., Heilmann L., et al. Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: a prospective randomized trial. Int J Oncol 16 (2000) 815-824
23. Bergqvist D., Agnelli G., Cohen A.T., Eldor A., Nilsson P.E., Le Moigne-Amrani A., et al. Prolonged prophylaxis against venous thromboembolism with enoxaparin in patients undergoing surgery for malignancy: 1-year survival study. J Thromb Haemost 1 Suppl 1 (2003) abstract number P1899
24. Lee A.Y., Rickles F.R., Julian A., Gent M., Baker R.I., Bowden C., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol 23 10 (2005) 2123-2129
25. Conti S, Guercini F, Iorio A. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1726 patients treated for at least three months. Pathophysiol Haemost Thromb. 2003/04;33:197-201.
26. Meyer G., Marjanovic Z., Valcke J., Lorcerie B., Gruel Y., Solal-Celigny P., et al. Comparison of low-molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 15 (2002) 1729-1735
27. Iorio A., Guercini F., and Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembloism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 1 (2003) 1906-1913
28. Ferretti G, Bria E, Giannarelli D, Carlini P, Felici A, Mandala M, et al. Does low-molecular-weight heparin influence cancer-related mortality? Ann Oncol 2006 May 2; [Epub ahead of print].
29. Hull R.D., Raskob G.E., Pineo G.F., Green D., Trowbridge A.A., Elliott C.G., et al. Subcutaneous low molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Eng J Med 326 (1992) 975-982
30. Lensing A.W., Prins M.H., Davidson B.L., and Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis. Arch Intern Med 155 6 (1995) 601-607
31. Siragusa S., Cosmi B., Piovella F., Hirsh J., and Ginsberg J.S. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 100 (1996) 269-277
32. Hettiarachchi R.J., Smorenburg S.M., Ginsberg J., Levine M., Prins M.H., Buller H.R., et al. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. J Thromb Haemost 82 2 (1999) 947-952
33. Gould M.K., Dembitzer A.D., Doyle R.L., Hastie T.J., and Garber A.M. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: a meta-analysis of randomized, controlled trials. Ann Intern Med 130 10 (1999) 800-809
34. Hutten B.A., Prins M.H., Gent M., Ginsberg J., Tijssen J.G., and Buller H.R. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism is relation to both malignancy and achieved International Normalized Ratio: a retrospective analysis. J Clin Oncol 18 17 (2000) 3078-3083
35. Altinbas M., Coskun H.S., Er O., Ozkan M., Eser B., Unal A., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small-cell lung cancer. J Thromb Haemost 2 (2004) 1266-1271
36. Kakkar A.K., Levine M.N., Kadziola Z., Lemoine N.R., Low V., Patel H.K., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol 22 10 (2004) 1944-1948
37. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23(10):2130-2135. Epub 2005 Feb 7.
38. Sideras K., Schaefer P.L., Okuno S.H., Sloan J.A., Kutteh L., Fitch T.R., et al. Low-molecular-weight heparin in patients with advanced cancer: a phase 3 clinical trial. Mayo Clin Proc 81 6 (2006) 758-767
39. Pini M., Aiello S., Manotti C., Pattacini C., Quintavalla R., Poli T., et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 72 2 (1994) 191-197
40. Das S.K., Cohen A.T., Edmondson R.A., Melissari E., and Kakkar V.V. Low-molecular-weight-heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 20 (1996) 521-526
41. Gonzalez-Fajardo J.A., Arreba E., Castrodeza J., Perez J.L., Fernandez L., Agundez I., et al. Venographic comparison of subcutaneous low-molecular weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 30 2 (1999) 283-292
42. Lopaciuk S., Bielska-Falda H., Noszczyk W., Bielawiec M., Witkiewicz W., Filipecki S., et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 81 1 (1999) 26-31
43. Veiga F., Escriba A., Maluenda M.P., Lopez Rubio M., Margalet I., Lezana A., et al. Low molecular weight heparin (enoxaparin) versus oral anticoagulant therapy(acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 84 4 (2000) 559-564
44. Lopez-Beret P., Orgaz A., Fontcuberta J., Doblas M., Martinez A., Lozano G., et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 33 1 (2001) 77-90
45. Koopman M.M., Prandoni P., Piovella F., Ockelford P.A., Brandjes D.P., van der Meer J., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 334 11 (1996) 682-687
46. [No authors listed] Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997;337(10):657-62.
47. Duroux P. A randomized trial of subcutaneous low molecular weight heparin(CY216) compared with intravenous unfractionated heparin in the treatment of deep vein thrombosis. A Collaborative European Multi-centre study. Thromb Haemost 65 (1991) 251-256
48. Simonneau G., Sors H., Charbonnier B., Page Y., Laaban J.P., Azarian R., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: evaluations dans l'Embolie Pulmonaire. N Engl J Med 337 10 (1997) 663-669
49. Simonneau G., Charbonnier B., Decousus H., Planchon B., Ninet J., Sie P., et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 153 13 (1993) 1541-1546
50. Bratt G., Tornebohm E., Granqvist S., Aberg W., and Lockner D. A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis. Thromb Haemost 54 4 (1985) 813-817
51. Holm H.A., Ly B., Handeland G.F., Abildgaard U., Arnesen K.E., Gottschalk P., et al. Subcutaneous heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Haemostasis 16 Suppl 2 (1986) 30-37
52. Faivre R., Neuhart E., Kieffer Y., Bassand J.P., and Maurat J.P. Efficacy of a very low molecular weight heparin fragment (CY 222) compared to standard heparin in patients with deep venous thrombosis. A randomized study. J Mal Vasc 12 Suppl B (1987) 145-146
53. Bratt G., Aberg W., Johansson M., Tornebohm E., Granqvist S., and Lockner D. Two daily subcutaneous injections of fragmin as compared with intravenous standard heparin in the treatment of deep venous thrombosis (DVT). Thromb Haemost 64 4 (1990) 506-510
54. Lindmarker P., Holmstrom M., Granqvist S., Johnsson H., and Lockner D. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 72 2 (1994) 186-190
55. Albada J., Nieuwenhuis H.K., and Sixma J.J. Treatment of acute venous thromboembolism with low molecular weight heparin(Fragmin). Results of a double-blind randomized study. Circulation 80 4 (1989) 935-940
56. Handeland G.F., Abildgaard U., Holm H.A., and Arnesen K.E. Dose adjusted heparin treatment of deep venous thrombosis: a comparison of unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 39 2 (1990) 107-112
57. Thery C., Simonneau G., Meyer G., Helenon O., Bridey F., Armagnac C., et al. Randomized trial of subcutaneous low-molecular-weight heparin CY 216(Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study. Circulation 85 4 (1992) 1380-1389
58. Luomanmaki K., Grankvist S., Hallert C., Jauro I., Ketola K., Kim H.C., et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med 240 2 (1996) 85-92
59. Fiessinger J.N., Lopez-Fernandez M., Gatterer E., Granqvist S., Kher A., Olsson C.G., et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 76 2 (1996) 195-199
60. Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M., et al. Randomized comparison of low-molecular-weight heparin versus oral anticoagulant therapy for the prevention of recurrent venous thromboembolism in patients with cancer (CLOT) investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349 2 (2003) 146-153
61. Kakkar V.V., Gebska M., Kadziola Z., Saba N., and Carrasco P. Bemiparin investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 89 4 (2003) 674-680
62. Ruf W., and Mueller B.M. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 32 Suppl 1 (2006) 61-68
63. Ossovskaya V.S., and Bunnett N.W. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84 (2004) 579-621
64. Belting M., Ahamed J., and Ruf W. Signalling of the tissue factor coagulation pathway in angiogenesis and cancer. Arterioscler Thromb Vasc Biol 25 (2005) 1545-1550
65. Bobek V, Kovarik J. Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother. 2004 May; 58(4):213-219 Review.
66. Hejna M., Raderer M., and Zielinski C.C. Inhibition of metastases by anticoagulants. J Natl Cancer Inst 91 (1999) 22-36
67. Folkman J. Role of angiogenesis in tumour growth and metastasis. Semin Oncol 29 (2002) 15-18
68. Hall J.G., Pauli R.M., and Wilson K.M. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 68 (1980) 122-140
69. Hasanbasic I., Cuerquis J., Varnum B., and Blostein M.D. Intracellular signalling pathways involved in Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 287 (2004) H1207-H1213
70. Healy A.M., Schwartz J.J., Zhu X., Herrick B.E., Varnum B., and Farber H.W. Gas 6 promotes Axl-mediated survival in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 280 (2001) L1273-L1281
71. O'Donnell K., Harkes I.C., Dougherty L., and Wicks I.P. Expression of receptor tyrosine kinase Axl and its ligand Gas6 in rheumatoid arthritis: evidence for a novel endothelial cell survival pathway. Am J Pathol 154 (1999) 1171-1180
72. Stenhoff J., Dahlback B., and Hafizi S. Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts. Biochem Biophys Res Commun 319 (2004) 871-878
73. Vajkoczy P., Knyazev P., Kunkel A., Capelle H.H., Behrndt S., von Tengg-Kobligk H., et al. Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumour cell growth and invasion and prolongs survival. Proc Natl Acad Sci USA 103 (2006) 5799-5804